AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Venetoclax plus obinutuzumab showed positive responses versus obinutuzumab plus chlorambucil including extended progression-free survival, with a demonstrated median time to next treatment of approximately eight years reflecting sustained durability.

  60% confidence

• The most frequently occurring Grade 3 (≥2%) adverse events in the venetoclax-based combination arm were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia, and leukopenia.

  60% confidence

• The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy, supporting first-line use of venetoclax-based combination regimens in broader CLL patient populations with unprecedented time to next treatment after one year of fixed-duration therapy.

  60% confidence

• Venetoclax plus obinutuzumab significantly improved PFS compared to chlorambucil plus obinutuzumab, with median PFS of 6.4 years versus 3.2 years (HR 0.50 [95% CI 0.39-0.63], p<0.001) after median follow-up of 9.2 years, and median TTNT of 7.6 years.

  60% confidence

Cited in these Via News reports

• FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies →
• Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →